| ISO 5910 First edition 2018-06 Cardiovascular implants and extracorporeal systems - Cardiac valve repair devices |
| Recognition Number | Cardiovascular |
| Recognition Date | 2019-01-14 |
| Recognition List | 051 |
| Recognition Number | 3-159 |
| Extent | Partial recognition. The following part(s) of the standard is (are) not recognized Section 7.2.4.2 Structural component fatigue assessment Section 7.2.5.3 Device durability assessment Section 7.4.6 Statistical considerations including sample and duration Annex N.3 Test parameters |
| Standards Orgs | ISO International Organization for Standardization https://www.iso.org/ |
| STG | Cardiovascular |
| FDA Tech | Changfu Wu FDA/OMPT/CDRH/ODE/DCD/SHDB/ 301-796-6086 changfu.wu@fda.hhs.gov |
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies. Section 7.2.4.2, Section 7.2.5.3, and Annex N3 conflict with section In Vitro Testing in reference #1 listed below. Section 7.4.6 conflicts with section Pediatric Clinical Trial Design in reference #2 listed below.
1.1 This document applies to all heart valve repair systems that have an intended use to repair and/or improve the function of native human heart valves by acting either on the valve apparatus or on the adjacent anatomy (e.g. ventricle, coronary sinus).
1.2 This document outlines an approach for verifying/validating the design and manufacture of a heart valve repair system through risk management. The selection of appropriate verification/validation tests and methods are derived from the risk assessment. The tests include assessments of the physical, chemical, biological, and mechanical properties of components and materials of heart valve repair systems. The tests also include preclinical in vivo evaluation and clinical investigation of the finished heart valve repair system to assess the safety and effectiveness of the heart valve repair system.
NOTE For the purposes of this document, effectiveness endpoint includes clinical performance and benefits.
1.3 This document defines operational conditions and performance requirements for heart valve repair systems where adequate scientific and/or clinical evidence exists for their justification.
1.4 This document excludes Cardiac Resynchronization Therapy (CRT) devices, paravalvular leakage closure devices, systems that do not leave an implant in place (e.g. ablation, radio frequency annuloplasty), apical conduits and devices with components containing viable cells. This Standard also excludes materials not intended for repairing and/or improving the function of human heart valves according to its intended use (e.g. patch material and sutures used in general surgical practice).
| Regulation Number | Device Name | Device Class | Product Code |
| Unclassified | Mitral Valve Repair Devices | Class 3 | NKM |
| 1. Fernando, A., Hillebrenner, M., Stewart, S., Swain, J., Hampshire, V., Zuckerman, B.(2011). U.S. Regulatory Considerations for Heart Valves Implanted by Minimally Invasive Surgery. Cardiovascular Engineering and Technology, 2(2): 62-5. 2. Yoganathan, A.P., Fogel, M., Gamble, S., Morton, M., Schmidt. P., Secunda, J., Vidmar, S., and Del Nido, P. (2013) A new paradigm for obtaining marketing approval for pediatric prosthetic heart valves. Journal of Thoracic and Cardiovascular Surgery, 146(4):879-86. |